Full metadata record

DC Field Value Language
dc.contributor.authorChoi, JH-
dc.contributor.authorShin, KM-
dc.contributor.authorKim, NY-
dc.contributor.authorHong, JP-
dc.contributor.authorLee, YS-
dc.contributor.authorKim, HJ-
dc.contributor.authorPark, HJ-
dc.contributor.authorLee, KT-
dc.date.accessioned2024-01-21T09:45:21Z-
dc.date.available2024-01-21T09:45:21Z-
dc.date.created2021-09-01-
dc.date.issued2002-11-
dc.identifier.issn0918-6158-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/139115-
dc.description.abstractThe present work was performed to elucidate the active moiety of a sesquiterpene lactone, taraxinic acid-1'-O-beta-D-glucopyranoside (1) from Taraxacum coreanum NAKAI on the cytotoxicity of various cancer cells. Based on enzymatic hydrolysis and MTT assay, the active moiety should be attributed to the aglycone taraxinic acid (1a), rather than the glycoside (1). Taraxinic acid exhibited potent antiproliferative activity against human leukemia-derived HL-60. In addition, this compound was found to be a potent inducer of HL-60 cell differentiation as assessed by a nitroblue tetrazolium reduction test, esterase activity assay, phagocytic activity assay, morphology change, and expression of CD14 and CD66b surface antigens. These results suggest that taraxinic acid induces the differentiation of human leukemia cells to monocyte/macrophage lineage. Moreover, the expression level of c-myc was down-regulated during taraxinic acid-dependent HL-60 cell differentiation, whereas p21(CIP1) and p27(KIP1) were up-regulated. Taken together, our results suggest that taraxinic acid may have potential as a therapeutic agent in human leukemia.-
dc.languageEnglish-
dc.publisherPHARMACEUTICAL SOC JAPAN-
dc.subjectC-MYC EXPRESSION-
dc.subjectINDUCTION-
dc.subjectAPOPTOSIS-
dc.titleTaraxinic acid, a hydrolysate of sesquiterpene lactone glycoside from the Taraxacum coreanum NAKAI, induces the differentiation of human acute promyelocytic leukemia HL-60 cells-
dc.typeArticle-
dc.identifier.doi10.1248/bpb.25.1446-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBIOLOGICAL & PHARMACEUTICAL BULLETIN, v.25, no.11, pp.1446 - 1450-
dc.citation.titleBIOLOGICAL & PHARMACEUTICAL BULLETIN-
dc.citation.volume25-
dc.citation.number11-
dc.citation.startPage1446-
dc.citation.endPage1450-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000179020200012-
dc.identifier.scopusid2-s2.0-1842869286-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusC-MYC EXPRESSION-
dc.subject.keywordPlusINDUCTION-
dc.subject.keywordPlusAPOPTOSIS-
dc.subject.keywordAuthortaraxinic acid-
dc.subject.keywordAuthordifferentiation-
dc.subject.keywordAuthorc-myc-
dc.subject.keywordAuthorp21(CIP1)-
dc.subject.keywordAuthorp27(KIP1)-
dc.subject.keywordAuthorHL-60 cell-
Appears in Collections:
KIST Article > 2002
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE